WARREN, N.J., Oct 11, 2011 (GlobeNewswire via COMTEX) -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm(R) drug delivery technology, announced that it has been granted Canadian patent No. 2,473,967 from the Canadian Intellectual Property Office, providing intellectual property protection in Canada for the Company's film products and methods of their preparation. The issued patent is comprised of 106 claims, of which 19 are independent. The claims cover Monosol Rx's proprietary technology, including film manufacturing processes, use of films to deliver actives to mammals, two layer films and film compositions. Important aspects of the patented technology allow manufacturers to maintain content uniformity throughout the film and create products that have a water content of 10% or less.
A. Mark Schobel, President and Chief Executive Officer of MonoSol Rx, stated, "We intend to maintain our leadership position in the development of drug-containing film products. Issuance of this critical patent in Canada continues our tradition of protecting our intellectual property and will enhance our ability to market PharmFilm(R) products competitively in this country in the future. As we have in the United States against BioDelivery Sciences International's ("BDSI") ONSOLIS product, we will continue to aggressively assert our patent rights regarding products and companies that are infringing any of our patent estate."
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver drugs in films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription drug products, a pipeline of prescription formulations based on PharmFilm(R) technology, and two recent FDA approvals - Zuplenz(R), the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone(R) sublingual film, the first and only combination film product delivering buprenorphine and naloxone for the treatment of opioid dependence.
For press releases and other company information visit www.monosolrx.com .
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: MonoSol Rx
CONTACT: MonoSol Rx:
Daniel Barber
Vice President, Business Development
(908) 941-1900
The Ruth Group (on behalf of MonoSol Rx)
Victoria Aguiar (media)
(646) 536-7013
[email protected]
Joshua Drumm, Ph.D. (investors)
(646) 536-7006
[email protected]